Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

IDEXX LABORATORIES INC /DE (IDXX)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $700.65 (close 2026-11-16); latest close $676.21 (2026-11-20), -3.5% since the report; figures re-marked at the latest close

Conclusion: WATCH

Conviction low · base case -50% · downside -68% · upside +14%

The market is paying 46.7x TTM net income for IDXX at $700.65, while the peer median P/E is 22.3x across three peers; the reverse DCF needs +10.8% revenue growth a year for 10 years at a 28.0% FCF margin, versus +10.4% delivered in the latest fiscal year. With only three peers setting the peer multiple, the anchor is weak, so conviction is low and the label is WATCH. The base case is -52.2% to $334.57, P/E at 22.3x, the peer median P/E. The downside is -69.4% to $214.13, the base case's multiple on -36.0% earnings, with the peers trading below the compressed multiple. The upside is +10.0% to $770.72, +10% earnings at today's P/E of 46.7x. The cases leave little reward against much larger downside, but the weak peer set and the gap between priced-in and delivered growth support that label rather than a higher-conviction call.

Key numbers

  • Share price: $676.21
  • Market cap: $53.28B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $4.66B
  • EV / EBITDA (TTM): 32.1x
  • P/E (TTM): 45.1x
  • FCF yield: 2.5%
  • Price / book: 28.50x
  • Earnings-quality flags (TTM): none flagged
  • EV / FCF (TTM): 41.0x
  • Revenue growth (latest fiscal year): +10.4%
  • ROIC (TTM): 55.5%
  • WACC: 7.5%
  • Economic profit spread: +47.9 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    IDEXX makes money mostly on recurring companion-animal diagnostics: of FY2025 revenue of $4,303,702K, CAG was $3,953,285K and CAG Diagnostics recurring revenue alone was $3,407,199K, with capital instruments ($200,206K, +51.8%) placed to feed consumable and reference-lab volume. Total FY2025 revenue rose 10.4% reported and 9.6% organic, gross margin rose 80bp to 61.8% and income from operations reached $1,360,031K (31.6% of revenue), with FY2025 operating cash flow of $1,181,805K against $124.7M of capex and $1.22B of buybacks. Between the FY2020 and FY2025 reports the mix has shifted further toward CAG recurring diagnostics and veterinary software, while LPD has shrunk in profit terms (FY2025 segment income $3,229K, down 51.3%) and Water and instrument sales recovered from their Covid-suppressed FY2020 levels.

  2. ✓ 2. Competitive advantage

    The record reads like a durable advantage, not a commodity: gross margin held 59.3%-62.7% and operating margin climbed from 25.6% (FY2020) to 31.6% (FY2025) and 32.4% (TTM to 2026-09-30), with revenue up every year from $2.71B to $4.30B and $4.66B on TTM, and net income tracking operating income ($1.06B FY2025 against $1.36B operating income), so no one-off made the record. It is earned on differentiation (ease of use, speed, accuracy, an integrated instrument-plus-information system) plus regulatory approval barriers (APHIS, EPA, FDA-validated tests) and a supply lock-up on Catalyst chemistry slides through 2044. It is not unassailable: Mars/Antech/Heska, Zoetis/Abaxis, Fujifilm, Covetrus and others compete, some with far greater resources, and consolidated corporate hospital groups that own reference labs can shift testing away. Capital returns are high (net income $1.06B on total equity of $1.61B in FY2025) and cash generation funds buybacks ($1.22B FY2025), shrinking diluted shares from 86.72M to 79.33M.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue rose 9.9% reported and 10.0% organic to $1.214 billion, with CAG Diagnostics recurring revenue up 10.8% reported and 11.0% organic; gross margin was 62.9% and operating margin 33.1%. EPS of $4.01 included a $0.03 non-operating equity-investment gain and a $0.01 share-based-compensation tax benefit. 2026 guidance was raised for revenue to $4,741-$4,767 million and EPS to $14.96-$15.16, while the reported operating-margin outlook was lowered to 32.1%-32.3%. The 10-Q says no material risk-factor changes from the 2025 Annual Report.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans